Loading clinical trials...

A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women With Osteoporosis

NCT00389740•Organon and Co

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.

Eligibility

Age

40 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patient is postmenopausal (or surgically menopausal) for at least 6 months
•Patient must be diagnosed with osteoporosis
•Patient has spinal anatomy suitable for DEXA of the lumbar spine

Exclusion Criteria

•Patient is receiving or has received treatment prior to randomization which might influence bone turnover
•Patient has a history of or evidence for metabolic bone disease (other than postmenopausal bone loss)
•Patient is receiving or is expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism

Key Dates

Start Date

April 2, 2001

Primary Completion Date

January 16, 2003

Completion Date

January 16, 2003

Last Updated

August 14, 2024

Enrollment

400

ACTUAL participants

Conditions

Osteoporosis, Postmenopausal

Interventions

MK0217, /Duration of Treatment : 12 Months

DRUG

Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months

DRUG

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

NCT05575167

Osteoporosis, Postmenopausal

View study

RECRUITINGNA

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

NCT05228262

Osteoporosis, Postmenopausal

View study

WITHDRAWNPHASE4

Effect of Mechanical Loading With PTH on Cortical Bone

NCT03232476

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

Inclusion Criteria

Exclusion Criteria

Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

Effect of Mechanical Loading With PTH on Cortical Bone

A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)

Efficacy and Safety of MW031 in PMO Subjects

ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women